Hormonal
Post-bariatric recurrent weight gain (RWG) can be managed with other FDA-approved anti-obesity medications including phentermine/topiramate, naltrexone/bupropion, and orlistat, which reduce weight regain or aid weight loss.
If GLP-1 injections are not suitable or effective for your post-surgery weight regain, ask your doctor about other FDA-approved oral medications. Options include phentermine/topiramate, naltrexone/bupropion, and orlistat. These drugs have different mechanisms and side effect profiles, so your doctor can help you choose the best fit. They are proven to help with weight loss and managing RWG.
Anti-obesity medicine (AOM) options that are currently approved by the US Food and Drug Administration (FDA) include... phentermine, phentermine/topiramate extended release (ER), naltrexone sustained release (SR) /bupropion sustained release (SR) and orlistat (52).
Source
Prognosticating post-bariatric surgery outcomes and management of postoperative recurrent weight gain and diabetes recurrence
Xiao He et al. · Frontiers in Nutrition · 2024
DOI 10.3389/fnut.2024.1510403
More from this paper
- Post-bariatric recurrent weight gain (RWG) can be effectively managed with FDA-approved anti-obesity medications (AOMs) such as GLP-1 receptor agonists (liraglutide, semaglutide), phentermine/topiramate, naltrexone/bupropion, and orlistat, which reduce weight regain or aid weight loss.Good
- Endoscopic interventions such as Endoscopic Sleeve Gastroplasty (ESG) and Transoral Outlet Reduction (TORe) are effective minimally invasive treatments for managing post-bariatric recurrent weight gain (RWG).Good
- Conversional surgeries (e.g., RYGB, SADI-S, DS) are effective for managing post-bariatric recurrent weight gain (RWG) and diabetes recurrence, but carry higher risks of complications compared to primary surgery.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →